Catheterization time Conventional transurethral resection Cáncer vesical primario no músculo-infltrante Duración de la estancia hospitalaria En-bloc transurethral resection Length of hospital stay Primary non-muscle invasive bladder cancer Recurrence Recurrencia Resección transuretral convencional Resección transuretral en bloque Tiempo de sondaje

Humans Male *Urinary Bladder Neoplasms Reproducibility of Results ROC Curve Image Interpretation Computer-Assisted Muscles Magnetic Resonance Imaging Retrospective Studies Bladder cancer Inter-reader agreement Meta-analysis Reliability Vi-rads

Administration Intravesical *Carcinoma Transitional Cell/pathology Epirubicin/therapeutic use Female Humans Male Mitomycin/therapeutic use Neoplasm Recurrence Local Randomized Controlled Trials as Topic *Urinary Bladder Neoplasms/pathology Intravesical Chemotherapy Non-muscle Invasive Bladder Cancer Turb

Cystectomy/adverse effects Female Humans Male Network Meta-Analysis *Urinary Bladder Neoplasms/pathology/surgery Urologic Surgical Procedures Tueb Turbt bladder cancer en bloc transurethral en bloc transurethral resection

*Cystectomy Humans Prospective Studies Systematic Reviews as Topic Treatment Outcome Urinary Bladder/pathology/surgery *Urinary Bladder Neoplasms/pathology/surgery models mortality nomograms radical cystectomy urinary bladder neoplasms

adjuvant chemotherapy bladder cancer cystectomy

Apoptosis B7-H1 Antigen/genetics/metabolism *Carcinoma Transitional Cell/pathology Cystectomy Humans Immune Checkpoint Inhibitors Ligands Lymph Node Excision Neoplasm Recurrence Local/pathology Prognosis Programmed Cell Death 1 Receptor Urinary Bladder *Urinary Bladder Neoplasms/pathology bladder urothelial carcinoma meta-analysis prognostic value programmed cell death ligand-1 radical cystectomy commercial or financial relationships that could be construed as a potential conflict of interest.

Administration Intravesical *Carcinoma Transitional Cell/pathology Humans Male Neoplasm Invasiveness/pathology Neoplasm Recurrence Local/pathology Neoplasm Staging *Urinary Bladder Neoplasms/drug therapy/therapy

Humans *Carcinoma Transitional Cell/diagnosis/therapy *Urinary Bladder Neoplasms Systematic Reviews as Topic Kidney Oregon *Ureteral Neoplasms/diagnosis/therapy Utuc renal pelvis cancer upper tract urothelial cancer ureteral cancer urothelial cancer

*Carcinoma Transitional Cell/pathology Female Humans Male Neoplasm Invasiveness Nephroureterectomy Sweden *Urinary Bladder Neoplasms/pathology Swedish national guidelines Urothelial carcinoma non-muscle invasive bladder cancer upper tract urothelial carcinoma

bladder cancer cohort cruciferous vegetables meta-analysis risk commercial or financial relationships that could be construed as a potential conflict of interest.

Humans Administration Intravesical Antibiotics Antineoplastic/administration & dosage Hematuria/drug therapy *Mitomycin/administration & dosage Prospective Studies Quality of Life Treatment Outcome *Urinary Bladder Neoplasms/drug therapy/pathology/surgery

Antineoplastic Combined Chemotherapy Protocols/therapeutic use *Carcinoma Transitional Cell/pathology Cisplatin/therapeutic use Cystectomy Humans Muscles/pathology Neoadjuvant Therapy Neoplasm Invasiveness *Urinary Bladder Neoplasms/pathology Bladder cancer Muscle-invasive Urothelial from MSD and BMS and Speaker and Other from AstraZecena. BPV reports Advisory Board Speaker and Other from Astellas Roche BMS and Merk-Pfizer Advisory Board and Other from Ipsen Advisory Board and Speaker from EUSA and MSD and Advisory Board from Sanofi. IPF report Advisory Board Speaker and Other from Pfizer Speaker and Other from Ipsen and Roche Advisory Board from EUSA and BMS and Speaker from Novartis and MSD. OFC reports Advisory Board and Speaker from Ipsen and Astellas Advisory Board from BMS and Pfizer-Merck and Speaker from AstraZeneca. AGA has received research funding from Astellas travel grants from Astellas Jansen Sanofi BMS Roche Pfizer and Ipsen and honoraria for speaker engagements advisory boards and continuous medical education from Janssen Astellas Sanofi Bayer Roche Ipsen BMS MSD Pfizer Eusa Pharma Eisai and AstraZeneca. JAA reports honoraria from Astellas Pfizer and BMS conulting or advisory role from Pfizer Astellas Janssen-Cilag MSD Oncology BMS Merck AstraZeneca Bayer and Eisai and Research Funding from BMS. RMB SVE CCD and MDS have nothing to disclose.

Area Under Curve Female Humans Male Neoplasm Recurrence Local/diagnosis Prospective Studies Recurrence Sensitivity and Specificity *Urinary Bladder Neoplasms/diagnosis Biomarker Bladder cancer Diagnostic accuracy Systematic review Xpert

#BladderCancer #blcsm #uroonc cystoscopy gross appearance multiplicity non-muscle-invasive bladder cancer progression recurrence size

*Carcinoma Transitional Cell/drug therapy/pathology Cisplatin Female Humans Male *Urinary Bladder Neoplasms/drug therapy/pathology *Urology *Bladder cancer *European Association of Urology *Guidelines *Immunotherapy *Metastatic *Systemic therapy *Urothelial carcinoma

*Carcinoma Transitional Cell/pathology/surgery Combined Modality Therapy Consensus Humans Neoplasm Invasiveness/pathology Quality of Life Urinary Bladder/pathology/surgery *Urinary Bladder Neoplasms/drug therapy/surgery Bladder neoplasms Bladder preservation Expert consensus Multi-disciplinary treatment

*Carcinoma Transitional Cell/pathology Humans Prognosis Retrospective Studies *Ureteral Neoplasms *Urinary Bladder Neoplasms *Urologic Neoplasms/pathology Carcinoma Transitional Cell Pathology

Cystectomy France Humans Lymphatic Irradiation Palliative Care Patient Positioning Radiation Oncology Radiotherapy Dosage Radiotherapy Adjuvant Radiotherapy Conformal Urinary Bladder Neoplasms/diagnostic imaging/pathology/*radiotherapy/surgery Bladder cancer Cancers de la vessie Chemoradiation Chimioradiothérapie French society for radiation oncology Guidelines Radiation therapy Radiothérapie Recommandations Société française de radiothérapie oncologique

Autoantigens Biomarkers Tumor/genetics/metabolism Gene Expression Regulation Neoplastic Humans Procollagen-Lysine 2-Oxoglutarate 5-Dioxygenase/genetics/metabolism Prognosis *Urinary Bladder Neoplasms/pathology Bladder cancer Meta-analysis Microarray datasets Overall survival Prognostic biomarker